Securities Fraud Investigation Into Corcept Therapeutics Incorporated (CORT) Announced – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz

LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz announces an investigation of Corcept Therapeutics Incorporated (“Corcept” or the “Company”) (NASDAQ: CORT) on behalf of investors concerning the Company’s possible violations of federal securities laws.

IF YOU ARE AN INVESTOR WHO LOST MONEY ON CORCEPT THERAPEUTICS INCORPORATED (CORT), CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING A CLAIM TO RECOVER YOUR LOSS.

What Is The Investigation About?

On December 31, 2025, Corcept announced the U.S. Food and Drug Administration (“FDA”) had issued a Complete Response Letter (“CRL”), declining to approve the Company’s New Drug Application (“NDA”) for relacorilant as a treatment for patients with hypertension secondary to hypercortisolism. The Company stated it was “surprised and disappointed by this outcome.”

On this news, Corcept’s stock price fell $35.40 per share, or 50.42%, to close at $34.80 per share on December 31, 2025.

Then, on January 29, 2026, the FDA published an updated CRL regarding Corcept’s relacorilant NDA. The updated letter revealed that “[d]uring the pre-submission meetings, [the FDA] informed [Corcept] on several occasions of [its] concerns about the adequacy of the clinical development program to assess the effect of relacorilant” and “to expect significant review issues if [Corcept] were to submit [its] application.”

On this news, Corcept’s stock price fell $4.71, or 10.6%, to close at $39.87 per share on January 30, 2026, thereby injuring investors.

Contact Us To Participate or Learn More:

If you purchased Corcept securities, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact us:

The Law Offices of Frank R. Cruz,
2121 Avenue of the Stars, Suite 800,
Century City, California 90067
Call us at: 310-914-5007
Email us at: [e-mail]
Visit our website at: www.frankcruzlaw.com.
Follow us for updates on Twitter at twitter.com/FRC_LAW.

If you inquire by email, please include your mailing address, telephone number, and number of shares purchased.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.